Navigation Links
Mouse Allergen Found In Homes Could Trigger Asthma In Kids

The amount of mouse allergen found in the air in many inner-city homes could be significant enough to trigger asthma symptoms // in children say researchers.

According to researchers children living in inner-city homes are continuously exposed to the allergy-causing substance found in mouse urine that is circulating in the air and exposure increases their risk for developing allergic sensitivity to mice, just as it does for laboratory workers who work with rodents.

Prior to this study, airborne mouse allergens had not been measured in inner-city homes, and their relationship to settled dust mouse allergen levels was unknown. Researchers conducted a study which involved 100 inner-city, school-age children with asthma. Each of the children underwent skin testing, and their homes were inspected to measure air and settled dust in their bedrooms.

In conclusion researchers say airborne mouse allergen levels in many inner-city homes may be similar to those found in animal facilities, where levels are significantly high and will elicit asthma symptoms. Thus to reduce the amounts of mouse allergens, researchers recommend rodent exterminations, sealing holes and cracks in homes, and educating families to clean up all food remains.
'"/>




Page: 1

Related medicine news :

1. Researchers Develop Mouse Model Of Brain Tumor
2. German Scientists Create Stem Cells From Mouse Testes
3. Mouse Models To Determine The Cause Of Aggressive Leukemia
4. Mouse Model Beneficial to Study of Head and Neck Cancer
5. Scientists Discover New RNAs in Mouse Testicles
6. Scientists Isolate Leukemia Stem Cells in Mouse Model
7. Mouse Model Demonstrates Immune System Reaction In Chlamydia Infection
8. Mouse Gene With Gene Stutter Will Help Leukemia Research
9. Rett Syndrome Reversed in Genetic Mouse Model
10. Treatment Extends Survival in Mouse Model of Spinal Muscular Atrophy
11. Mouse Study Suggests Anxiety Disorders Take Root in Infancy

Post Your Comments:
(Date:11/25/2009)...ation and treatment clinics to resume Monday, Nov....ovember 25, 2009 -- Centegra Health System is cont...ne shots at four Centegra Primary Care (CPC) vacci...as arrived. The clinics are at CPC sites in Huntle... open as follows: ,   From 4:30 to 7:3...
(Date:11/25/2009)...ological symptoms, study finds , , WEDN...de effects are among the potential problems faced ...re treated with cisplatin-based chemotherapy, a ne...orwegian men treated for unilateral testicular can...w-up survey conducted from 1998 to 2002. , The ...
(Date:11/25/2009)...re/-- MISSIONSkincare ®isproudtosupportGNC,se...NC,sannualSt.Jude ThanksandGiving campaign,$1fromt...ER-C(TM)LipBalm willbedonatedtoSt.Jude.Additionall...onationatcheckoutatoneoftheir5,000+retaillocations...Judeduringtheir2009 ThanksandGiving campaign. ,...
(Date:11/25/2009)...nforthe4thStraightYear ,, WASHINGTON,Nov.25/P...Georgia(LCA-GA)issuedthe 4thAnnualReportCardonLung...eagainstthislethaldiseaseinthestateofGeorgia.LCA-G...alorganizationdedicatedexclusivelytopatientsupport...r. ,, (Logo: http://www.newscom.com/cgi-bin/prn...
(Date:11/25/2009)...al cancer also can reverse a rare stomach disorder...he disease, researchers at Vanderbilt University M...se causes thickening of the stomach lining, severe...nemia and swelling in the feet and ankles due to p...stric cancer. Previously, the only effective treat...
Breaking Medicine News(10 mins):Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2Health News:Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer 2Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2
...an research groups are undertaking pioneering stud...ing to patients receiving new drug treatments as e...fessor Shaun Jackson from The Australian Centre fo...tigating the impact of the bone marrow microenviro...
...arch 9, 2009 An easily implementable technique to...ed through angioplasty and stent insertion has bee...nsky of the Hebrew University of Jerusalem. , A... to part of the beating heart, usually due to plaq...
...n California Practice to Join SpectraScience Netwo...ystem , , SAN DIEGO, March 9 SpectraScience, Inc...dical device company, today announced that it has ... founder of Women,s Integrative Health, stated, "W...
...March 9 CEL-SCI Corporation (NYSE Alternext US: C...clusive licensing agreement with Byron Biopharma (...exclusive license to market and distribute the Com...th Teva Pharmaceuticals and Orient Europharma. , ...
... Journal of Radiation Oncology*Biology*Physics Stu...stem Provides Enhanced Image Information for Plann...REAL, March 4 Researchers report in the February ... enhanced image information to enable radiation on...
...., March 9 VirtualHealth Technologies, Inc. (OTC ...ve immediately it,s subsidiary Envoii Healthcare, ...o better reflect it,s focus on eHealth Security pr...t on growing our opportunities in this evolving cl...
Other Medicine News:Health News:World first treatment for leukemia being developed in Australia 2Health News: Hebrew University scientist develop technique for eliminating reblockage of arteries 2Health News:Women's Integrative Health Encinitas OB/GYN Selects LUMA Cervical Imaging System 2Health News:Women's Integrative Health Encinitas OB/GYN Selects LUMA Cervical Imaging System 3Health News:CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine(R) for Republic of South Africa 2Health News:Published Data Confirms First 3D Ultrasound for Breast Cancer Treatment Planning Helps Radiation Oncologists Better Define Treatment Region 2Health News:Published Data Confirms First 3D Ultrasound for Breast Cancer Treatment Planning Helps Radiation Oncologists Better Define Treatment Region 3Health News:Published Data Confirms First 3D Ultrasound for Breast Cancer Treatment Planning Helps Radiation Oncologists Better Define Treatment Region 4Health News:Envoii Healthcare, LLC is now Secure eHealth, LLC 2Health News:Envoii Healthcare, LLC is now Secure eHealth, LLC 3
(Date:11/25/2009)....,Nov.25/PRNewswire/--CempraPharmaceuticalsInc.tod...iefexecutiveofficer,willpresentatthePiperJaffray21...1,2009,atTheNewYorkPalaceHotelinNewYorkCity.Dr.Fer...gantibioticclinicalprogramsforthetreatmentofdrug-r...Pharmaceuticals ,, Foundedin2006,CempraPharmac...
(Date:11/25/2009)...alif.,Nov.25/PRNewswire/-- ChemoCentryx,Inc.,anno...y,sPROTECT-1(theProspectiveRandomizedOralTherapyEv...X282-B)inpatientswithmoderate-to-severeCrohn,sdise...yandtolerabilityprofile.Thestudydemonstratedeviden...yasdefinedasa70-pointdecreaseintheCrohn,sDiseaseAc...
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--Vermillion,Inc.(VRM...nofReorganizationandDisclosureStatementtoday,Novem...eDistrictofDelaware.Ahearingtoconsiderapprovalofth...r8,2009,withthehearingontheconfirmationofthePlansc...ompanytopayallclaimsinfull.ThePlanisexpected,ifapp...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3Sunesis Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 6012 1Sunesis Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 6012 2Sunesis Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 6012 3Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 1Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 2Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 3Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 4Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 5Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 6Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 7Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 8Competitive Technologies Selects RF 7CBinder as Public Relations Agency of Record 6008 1Competitive Technologies Selects RF 7CBinder as Public Relations Agency of Record 6008 2Competitive Technologies Selects RF 7CBinder as Public Relations Agency of Record 6008 3
... increase in advanced non-small cell, lung cancer ...clitaxel and cisplat...include reductions in chemotherapy-indu...OKYO, March 18 BioNumerik,Pharmaceuticals, Inc. (...ASKA") today announced the results of a Phase III ...
... 2b in Second Quarter of 2008 - - Conferen... DIEGO, March 17 Ardea Biosciences, Inc.,(Nasdaq:...lts from its,ongoing Phase 2a proof-of-concept stu...oside reverse transcriptase inhibitor (NNRTI), in,... Preliminary results from the first two of three ...
Other Medicine Technology:BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM) 2BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM) 3BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM) 4BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM) 5Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 2Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 3Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 4
UPJ Occlusion Balloon Catheter
Omega NV Balloon Ureteral Dilator Sets
AquaGuide Ureteral Access Sheath
Flexible Ureteroscopy Sheath Set
Medicine Products: